The global chikungunya fever drugs market is anticipated to grow at a significant CAGR 6.3% during the forecast period (2022-2028). Chikungunya is a mosquito borne viral disease caused by the RNA virus belonging to the alphavirus genus of family Togaviridae. Its transmission from human to human is facilitated by the bites of infected female mosquitoes. The prevalence of chikungunya fever has been reported in more than 60 countries of Asia, Africa, Europe and the Americas, to date. Most commonly, the genus of mosquitoes responsible for the cause of the disease include Aedes aegypti and Aedes albopictus. Presently, there is no cure for the disease, although the treatments are focused only to address the symptoms. In 2019, according to the World Health Organization, 349 936 suspected and 146 914 laboratory confirmed cases of chikungunya were reported to the PAHO regional office. Countries that reported the most cases were Brazil (265,000 suspected cases), Bolivia and Colombia (19,000 suspected cases, respectively). 

Further, in September 2019, according to the European Centre for Disease Prevention and Control, there were about 102 autochthonous chikungunya cases in Italy. Such trends for chikungunya fever were seen across the region. This is expected to boost the market growth during the forecasted period. Growing geriatric population coupled with the poor hygienic conditions are the major concerns that increase the risk factor for chikungunya. Additionally, the increasing R&D investments by the key market players are likely to provide a boost to the global chikungunya fever drugs market during the forecast period. Moreover, the increasing government investments and favorable policies will fuel the market. 

Market Coverage

• The market number available for – 2021-2028

• Base year- 2021

• Forecast period- 2022-2028

• Segment Covered- 

o By Product Type

o By End-User

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape: Abivax SA, Merck & Co.  Inc., and Bharat Biotech International Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Chikungunya Fever Drugs Market Report by Segment

By Product Type

• Vaccine

• Monoclonal Antibodies

• Synthetic Peptides

• Others

By End-User

• Hospitals 

• Clinics

• Others

Global Chikungunya Fever Drugs Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa